Sugi Predict

Sugi Predict / Compounds / SCHEMBL334795

SCHEMBL334795

SCHEMBL334795

CCC(C)OC(=O)C(CC)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.44
▸ FAAH O00519 1/20 0.33
▸ MMP1 P03956 1/20 0.32
▸ MMP2 P08253 1/20 0.32
▸ MMP3 P08254 1/20 0.32
▸ MMP9 P14780 1/20 0.32
▸ MMP13 P45452 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ CA2 P00918 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ CHRM1 P11229 2/20 0.31
▸ AKR1A1 P14550 1/20 0.31
▸ CHRM3 P20309 1/20 0.31
▸ HTR2A P28223 1/20 0.31
▸ HTR2C P28335 1/20 0.31
▸ ADRA1A P35348 1/20 0.31
▸ HRH1 P35367 1/20 0.31
▸ DRD3 P35462 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28889016 0.91 MAPT (0.42) MAPTFAAHCA2CHRM1CHRM3
SCHEMBL27944130 0.87 FAAH (0.39) MAPTFAAHCHRM1ALDH1A1TSHR
SCHEMBL7755041 0.85 MAPT (0.41) MAPTFAAH
SCHEMBL1706068 0.85 MAPT (0.41) MAPTFAAH
SCHEMBL335608 0.85 MAPT (0.41) MAPTMMP1MMP2MMP3MMP9
SCHEMBL335124 0.85 CHRM1 (0.41) MAPTFAAHCA2MAPK1CHRM1
SCHEMBL27561060 0.84 FAAH (0.40) MAPTFAAHCHRM1ALDH1A1TSHR
SCHEMBL10807031 0.84 MAPT (0.40) MAPTMMP1MMP2MMP3MMP9
SCHEMBL1010642 0.84 MAPT (0.40) MAPTFAAHMMP1MMP2MMP3
SCHEMBL15549609 0.83 MAPT (0.38) MAPTMEN1KMT2ATDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115768493-A Devices and compositions for improved scent delivery 宝洁公司 2023-03-07 — — CN claimed
CN-115697425-A Devices and compositions for improved scent delivery 宝洁公司 2023-02-03 — — CN claimed
US-6415614-B1 CONTROLLING VAPOR PRESSURE OF MIXTURE VISTEON GLOBAL TECHNOLOGIES, INC. 2002-07-09 — — US claimed
CN-115768493-A Devices and compositions for improved scent delivery 宝洁公司 2023-03-07 — — CN disclosed
CN-115697425-A Devices and compositions for improved scent delivery 宝洁公司 2023-02-03 — — CN disclosed
CN-115279368-A Heteroaryl compounds 维瓦斯治疗公司 2022-11-01 — — CN disclosed
CN-107078352-B Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery using same 三菱化学株式会社 2020-04-28 — — CN disclosed
US-8222404-B2 [1,2,4]Thiadiazin-3-yl acetic acid compound and methods of making the acetic acid compound ANADYS PHARMACEUTICALS, INC. (US) 2012-07-17 — — US disclosed
US-20120116077-A1 [1,2,4]THIADIAZIN-3-YL ACETIC ACID COMPOUND[[S]] AND METHODS OF MAKING THE ACETIC ACID COMPOUND ANADYS PHARMACEUTICALS, INC. (US) 2012-05-10 — — US disclosed
US-8097613-B2 [1,2,4]thiadiazine 1,1-dioxide compounds ANADYS PHARMACEUTICALS, INC. (US) 2012-01-17 — — US disclosed
WO-2009152166-A1 [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2009-12-17 — — WO disclosed
WO-1997023465-A1 NEW BARBITURIC ACID DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS BOEHRINGER MANNHEIM GMBH (DE) 1997-07-03 — — WO disclosed
EP-0778263-A1 BENZENE COMPOUND AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1997-06-11 — — EP disclosed
US-5334747-A Reacting substituted malonic acid dialkyl ester with aniline in presence of stoichiometric amount of alkali alcoholate, neutralizing product with acid, saponifying with water HULS AKTIENGESELLSCHAFT (DE) 1994-08-02 — — US disclosed
EP-0060416-B1 NEW BETA-LACTAM ACETIC ACID DERIVATIVES, THE PROCESS FOR PREPARING THEM, AND THEIR USE AS INTERMEDIATES FOR 1-AZABICYCLO(3.2.0.)HEPT-2-ENE ANTIBIOTICS GRUPPO LEPETIT S.P.A. (IT) 1986-08-20 — — EP disclosed
US-4576746-A Novel β-lactam acetic acid derivatives GRUPPO LEPETIT, S.P.A. (IT) 1986-03-18 — — US disclosed
EP-0060416-A1 New beta-lactam acetic acid derivatives, the process for preparing them, and their use as intermediates for 1-azabicyclo(3.2.0.)hept-2-ene antibiotics GRUPPO LEPETIT S.P.A. (IT) 1982-09-22 — — EP disclosed
US-4097496-A ANTIPROSTAGLANDIN ACTIVITY HOECHST AKTIENGESELLSCHAFT (DT) 1978-06-27 — — US disclosed
US-4083990-A ANTIPROSTAGLANDIN EFFECT HOECHST AKTIENGESELLSCHAFT (DT) 1978-04-11 — — US disclosed
US-3984459-A ANTI-PROSTAGLANDINS HOECHST AKTIENGESELLSCHAFT (DT) 1976-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120116077-A1 [1,2,4]THIADIAZIN-3-YL ACETIC ACID COMPOUND[[S]] AND METHODS OF MAKING THE ACETIC ACID COMPOUND ACMSD, ACACA, ALDH1A1 MAPT 2195/4885FAAH 801/4885MMP1 3929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.